or Try an Advanced Search...

    Technical Analysis for HRMY - Harmony Biosciences Holdings, Inc.

    Grade Last Price % Change Price Change
    C 30.17 -4.16% -1.31
    HRMY closed down 4.16 percent on Friday, June 28, 2024, on 2.02 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
    6 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical HRMY trend table...
    Date Alert Name Type % Chg
    Fell Below 200 DMA Bearish 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Upper Bollinger Band Walk Strength -4.16%
    Above Upper BB Strength -4.16%
    Upper Bollinger Band Touch Strength -4.16%
    20 DMA Support Bullish -2.93%
    50 DMA Support Bullish -2.93%
    Crossed Above 200 DMA Bullish -2.93%
    MACD Bullish Centerline Cross Bullish -2.93%
    Upper Bollinger Band Walk Strength -2.93%
    Older End-of-Day Signals for HRMY ...

       Recent Intraday Alerts

    Alert Time
    Fell Below 200 DMA 1 day ago
    200 DMA Support 1 day ago
    Down 3% 1 day ago
    Fell Below Previous Day's Low 1 day ago
    Down 1 ATR 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    HRMY Chart by TradingView
    Basic chart:

    Profile

    Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Pharmaceutical Neurological Disorders Stage Pharmaceutical Ethers Urological Disorders Chloroarenes Narcolepsy Piperidines Rare Neurological Disorders Stimulants

    Is HRMY a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 25 HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
    Jun 24 Harmony wins Wakix label extension to include sleepiness in pediatric patients
    Jun 24 HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY
    Jun 21 Harmony Bio gains as Citi starts at Buy on risk-reward setup
    Jun 21 Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
    Jun 5 Harmony releases promising phase 2 results of pitolisant for myotonic dystrophy
    Jun 5 HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1
    May 28 HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE
    May 4 Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
    May 3 Harmony Biosciences Holdings First Quarter 2024 Earnings: EPS Beats Expectations
    See more HRMY news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 39.265
    52 Week Low 18.6112
    Average Volume 397,688
    200-Day Moving Average 30.37
    50-Day Moving Average 29.92
    20-Day Moving Average 29.90
    10-Day Moving Average 29.92
    Average True Range 1.23
    RSI (14) 51.46
    ADX 18.42
    +DI 27.13
    -DI 14.31
    Chandelier Exit (Long, 3 ATRs) 28.70
    Chandelier Exit (Short, 3 ATRs) 32.25
    Upper Bollinger Bands 31.21
    Lower Bollinger Band 28.59
    Percent B (%b) 0.6
    BandWidth 8.77
    MACD Line 0.16
    MACD Signal Line -0.01
    MACD Histogram 0.1672
    Fundamentals Value
    Market Cap 1.77 Billion
    Num Shares 58.6 Million
    EPS 2.47
    Price-to-Earnings (P/E) Ratio 12.21
    Price-to-Sales 3.82
    Price-to-Book 4.06
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 32.82
    Resistance 3 (R3) 33.10 32.49 32.38
    Resistance 2 (R2) 32.49 31.82 32.35 32.23
    Resistance 1 (R1) 31.33 31.40 31.03 31.05 32.08
    Pivot Point 30.73 30.73 30.58 30.59 30.73
    Support 1 (S1) 29.57 30.05 29.27 29.29 28.26
    Support 2 (S2) 28.96 29.64 28.82 28.11
    Support 3 (S3) 27.80 28.96 27.96
    Support 4 (S4) 27.52